| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.091 | 0.01 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | 0.091 | 0.02 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | TG-101348 | GDSC1000 | pan-cancer | AAC | 0.071 | 0.02 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.08 | 0.02 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | 0.13 | 0.02 |
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | -0.085 | 0.02 |
| mRNA | SGC0946 | GDSC1000 | pan-cancer | AAC | 0.087 | 0.02 |